Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $86.1 million.

  • Autolus Therapeutics' Cash & Equivalents fell 8689.27% to $86.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.1 million, marking a year-over-year decrease of 8689.27%. This contributed to the annual value of $227.4 million for FY2024, which is 508.67% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Cash & Equivalents of $86.1 million as of Q3 2025, which was down 8689.27% from $123.8 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Cash & Equivalents peaked at $758.5 million during Q1 2024, and registered a low of $86.1 million during Q3 2025.
  • For the 5-year period, Autolus Therapeutics' Cash & Equivalents averaged around $303.7 million, with its median value being $239.6 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 15625.14% in 2024, then crashed by 8737.03% in 2025.
  • Autolus Therapeutics' Cash & Equivalents (Quarter) stood at $310.3 million in 2021, then rose by 23.23% to $382.4 million in 2022, then plummeted by 37.36% to $239.6 million in 2023, then fell by 5.09% to $227.4 million in 2024, then crashed by 62.12% to $86.1 million in 2025.
  • Its Cash & Equivalents was $86.1 million in Q3 2025, compared to $123.8 million in Q2 2025 and $95.8 million in Q1 2025.